Nuvectis Pharma, Inc. (NASDAQ:NVCT) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares (follow-on public offering) Closed: US$115M raised Use of proceeds: Advance development of NXP100 in PNH and other complement-mediated diseases and the oncology portfolio | Aug 4, 2026 |
| Public offering of common stock Update: US$100M · US$20 a share · Cantor +6 Dealers: Cantor (lead), H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, Titan Partners, a division of American Capital Partners Use of proceeds: Advance NXP100, NXP200 and NXP900 programs, hiring, capital expenditures, public company costs and general corporate purposes | Jun 30, 2026 |
| At-the-market programme of shares Closed: at-the-market programme | Aug 5, 2025 |
| Public offering of common stock Closed: US$15.5M raised · US$5 a share · Lucid Capital Markets Dealers: Lucid Capital Markets (lead) Use of proceeds: Advance NXP800 and NXP900 development, hiring, capital expenditures, public company costs and general corporate purposes | Feb 7, 2025 |